Supplementation with NAD+ Precursors for Treating Alzheimer’s Disease: A Metabolic Approach
Journal of Alzheimer's Disease · 2024
DOI: 10.3233/jad-231277 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Alzheimer's Disease, 2024. Verfasst von Mohammed Alghamdi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Alzheimer Disease, NAD, Niacinamide, Pyridinium Compounds. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer’s disease (AD) is a progressive neurocognitive disorder. There is no cure for AD. Maintenance on intracellular levels of nicotinamide adenine dinucleotide (NAD+) has been reported to be a promising therapeutic strategy for the treatment of AD. NAD+ precursors that represent candidate targets include nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR).
Objective
This systematic review provides insights into the potential therapeutic value of NAD+ precursors including NMN and NR, for the treatment of AD using preclinical and clinical studies published in the last 5 years.
Methods
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol was followed to systematically search the literature using two databases.
Results
We found 3 studies that used NMN to treat AD in preclinical murine models. However, human clinical trials using NMN as a therapeutic intervention in AD was not available in the current literature. We also found 4 studies that investigated the potential benefits of NR for the treatment of AD in preclinical models. We also found 2 human clinical trials that showed marked improvements in plasma and neuroimaging biomarkers, and cognitive measures following supplementation with NR.
Conclusions
Results of preclinical and clinical studies confirm the potential benefits of NAD+ precursors for the treatment of AD. However, further clinical studies are required to confirm the increasingly important value of NAD+ precursors as effective pharmacological interventions in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, Australia.
- Department of Radiology and Medical Imaging, Faculty of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia.
Zitieren
APA
Alghamdi, M., & Braidy, N. (2024). Supplementation with NAD+ Precursors for Treating Alzheimer’s Disease: A Metabolic Approach. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-231277
Vancouver
Alghamdi M, Braidy N. Supplementation with NAD+ Precursors for Treating Alzheimer’s Disease: A Metabolic Approach. Journal of Alzheimer's Disease. 2024. doi:10.3233/jad-231277
BibTeX
@article{Alghamdi2024,
author = {Alghamdi, Mohammed and Braidy, Nady},
title = {Supplementation with NAD+ Precursors for Treating Alzheimer’s Disease: A Metabolic Approach},
journal = {Journal of Alzheimer's Disease},
year = {2024},
doi = {10.3233/jad-231277}
}
EUVIMED